Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia

被引:0
|
作者
Fang, Y [1 ]
Gratwohl, A
Van Houwelingen, HC
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Fac Epidemiol & Med Stat, Wuhan 430030, Peoples R China
[2] Kantonsspital, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland
[3] Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands
关键词
relapse; transplantation; bone marrow; chronic myeloid leukaemia;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To analyse the risk factors of relapse before bone marrow transplantation (BMT) and to present the prognostic information as good as possible. Methods A total of 3142 patients, who underwent the allogeneic blood or bone marrow transplantation between 1989 and 1997 and were documented in the European Group for Blood and Marrow transplantation (EBMT), were included. Six possible risk factors including type of donor, stage of disease, age, gender, donor-recipient sex combination and the waiting time from diagnosis to transplation of relapse were considered. The time to relapse was analysed by Kaplan-Meier curves and Cox regression with stratification on prognostic factors that did not satisfy the Proportional Hazard Assumption. Results An amount of 447 patients relapsed out of all 3142 patients. The relapse rate was 14.2%. Type of donor and stage of disease showed a clear prognostic effect, but failed the proportional hazard assumption. Therefore, the data were stratified on the combination of type of donor and stage of disease. Within these strata an additional significant effect of age could be observed. Relative risk of age, 40 vs age < 40 was 1.32 (95% confidence interval 1.09 - 1.59). The prognostic model is summarized graphically. Conclusions The combination of type of donor, stage of disease and age of recipient at transplantation are important prognostic factors for relapse after BMT.
引用
收藏
页码:305 / 308
页数:4
相关论文
共 50 条
  • [31] Adherence assessment in Chronic Myeloid Leukaemia patients treated by tyrosine kinase inhibitors
    Daouphars, M.
    Ouvry, M.
    Lenain, P.
    Rouvet, J.
    Varin, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 414 - 415
  • [32] Assessment of Changes of Membrane Properties and Platelets Function in Patients with Chronic Myeloid Leukaemia
    Popov, Viola
    Ana, Vladareanu Maria
    Mircea, Matei Bogdan
    Oktaviani, Matei Christien
    Moisescu, Mihaela Georgeta
    Eugenia, Kovacs
    Omer, Meilin
    Andreescu, Mihaela
    Patrinoiu, Oana
    Tudor, Savopol
    Bumbea, Horia
    BLOOD, 2017, 130
  • [33] The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
    Raanani, P
    Dazzi, F
    Sohal, J
    Szydlo, RM
    van Rhee, F
    Reiter, A
    Lin, F
    Goldman, JM
    Cross, NCP
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) : 945 - 950
  • [34] Outcome of allogeneic haematopoietic stem cell transplantation in patients with atypical chronic myeloid leukaemia
    Koldehoff, M.
    Elmaagacli, A. H.
    Ditschkowski, M.
    Beelen, D. W.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S428 - S428
  • [35] The quality of molecular remission after stem cell transplantation in patients with chronic myeloid leukaemia
    Lewandowski, K.
    Gil, L.
    Baranska, M.
    Iwola, M.
    Drozdowska, D.
    Lewandowska, M.
    Komarnicki, M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S317 - S317
  • [36] A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours
    Dominik Wolf
    Holger Rumpold
    Drug Safety, 2009, 32 : 1001 - 1015
  • [37] A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours
    Wolf, Dominik
    Rumpold, Holger
    DRUG SAFETY, 2009, 32 (11) : 1001 - 1015
  • [38] Appearance of multidrug resistance (MDR) as an early predictor of relapse in imatinib treated chronic myeloid leukaemia patients
    Rideg, O
    Teibert, A
    Magyarlaki, T
    Tökes-Füzesi, M
    Miseta, A
    Schmelczer, M
    Kovács, GL
    CLINICA CHIMICA ACTA, 2005, 355 : S285 - S285
  • [39] Current role of stem cell transplantation in chronic myeloid leukaemia
    Gratwohl, Alois
    Heim, Dominik
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2009, 22 (03) : 431 - 443
  • [40] Development of donor cell derived acute myeloid leukaemia after stem cell transplantation for chronic myeloid leukaemia
    Pieroni, F
    Oliveira, FM
    Moraes, D
    Straccieri, ABPL
    Rodrigues, MC
    Panepucci, RA
    Voltarelli, JC
    Simoes, BP
    Falcao, RP
    BONE MARROW TRANSPLANTATION, 2006, 37 : S219 - S220